Hepatocellular carcinoma (HCC) is the sixth most common type of malignant cancer. HCC causes more than 600,000 deaths annually, making it the third most frequent cause of cancer-related death. 1 HCC is an aggressive tumor with a poor prognosis and high mortality. Currently, an effective targeted therapy does not exist for HCC. Therefore, there is a clinical need for identifying a prognostic biomarker and a new therapeutic target for treatment of HCC. 2 Forkhead box (Fox) proteins are a family of transcription factors that share an evolutionarily conserved "winged-helix" DNA-binding domain. 3 The Fox protein family is further divided into 19 subclasses (FoxA to FoxS). The forkhead O (FoxO) subclass is one of the largest subgroups of Fox proteins and includes FoxO1, FoxO3, FoxO4, and FoxO6. 4 FoxO proteins regulate a wide spectrum of biological processes, including differentiation, cell cycle progression, DNA damage repair, and apoptosis.
In human cancers, FoxO3a is a tumor suppressor that regulates a variety of proapoptotic genes and is inactivated by the PI3k-Akt oncogenic pathway. 5 Protein expression of FoxO3a has been investigated in clinical samples of various types of cancers, including esophageal squamous cell carcinoma, ovarian cancer, hepatocellular carcinoma, breast cancer, nasopharyngeal carcinoma, gastric cancer, and lung adenocarcinoma. [6] [7] [8] [9] [10] [11] [12] [13] [14] Most of these studies reported a tumor-suppressive role for FoxO3a and found that tumors with high FoxO3a expression had a better patient survival rate. However, previous studies have also demonstrated that FoxO3a may serve an oncogenic function. FoxO3a has been shown to promote cancer cell survival, tumor expansion, and metastasis and to contribute to poor prognosis in several types of cancers through a variety of mechanisms. [15] [16] [17] [18] [19] Knockdown of FoxO3a expression in MDA-MB-231 breast cancer cells induces a decrease in tumor size in a xenograft model and inhibits invasion by regulating matrix metalloproteinases. 19 FoxO3a activates serotonin-induced cell proliferation in serum-deprived hepatocellular carcinoma cells. 16 These contradictory findings indicate that FoxO3a may have unique roles in different tumor types.
In this study, we analyzed the expression of FoxO3a in human HCC and normal liver specimens via immunohistochemistry (IHC) and immunoblotting. We compared expression of FoxO3a with various clinicopathologic characteristics and with patient prognosis. We next performed an in vitro study to determine the contribution of FoxO3a to cell proliferation and migration using small interfering RNAs (siRNAs) to downregulate FoxO3a expression in a human HCC cell line and assayed the effects on cell proliferation and wound healing.
Materials and Methods

Patients and Specimens
Of the 213 consecutive cases of HCC that underwent surgical resection between 1991 and 2013 at Hanyang University Hospital, Seoul, Korea, 187 cases had sufficient formalin-fixed, paraffin-embedded (FFPE) tumor and adjacent nonneoplastic liver tissues with complete clinical follow-up information. H&E-stained slides, pathology reports, and other medical records were collected and reviewed to confirm each diagnosis. This information was also used to establish clinicopathologic data regarding the tumors, such as histologic grade, primary tumor size, small or large vessel invasion, American Joint Committee on Cancer (AJCC) stage, multifocality, and clinical outcome. An additional four pairs of fresh-frozen HCC tumor and adjacent liver tissue samples were included in Western blot analysis. Twenty-one normal liver tissue samples were also obtained from patients who underwent surgical resection for blunt trauma or benign neoplasm. This study was approved by the Institutional Review Board (IRB) of the Hanyang University Hospital (IRB file No. 2015-12-017).
Construction of Tissue Microarray
H&E slides made from FFPE tissue blocks were reviewed to prepare fixed tissue specimens that had characteristic cellular morphology and were absent of necrotic areas. Single tissue cores, each 2.0 mm in diameter, were punched from each paraffin block and assembled into a recipient paraffin block using a tissue microarray (TMA) instrument (AccuMax Array; ISU ABXIS, Seoul, Korea). The TMA blocks contained 21 normal livers and 187 pairs of HCC and adjacent nonneoplastic liver tissues.
IHC
Immunohistochemical staining of the TMA slides was performed to evaluate the expression of FoxO3a and Ki-67 in HCC and adjacent liver tissues. The sections were first deparaffinized in xylene and then rehydrated through graded ethanol. For antigen retrieval, we autoclaved the slides at 100°C for 30 minutes in sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked using peroxidase blocking solution (S2023; Dako, Carpinteria, CA). The sections were incubated with primary antibodies (1:100 dilution) overnight at 4°C, followed by incubation with labeled polymer (K5007, DAKO REAL EnVision/HRP; Dako) for 30 minutes at room temperature. The primary antibodies were rabbit anti-human FoxO3a monoclonal antibody (clone D19A7, catalog No. 12929; Cell Signaling Technology, Beverly, MA) and mouse anti-human Ki-67 monoclonal antibody (M7240; Dako). 3,3′-Diaminobenzidine was used as a chromogen for detection, and Mayer hematoxylin was applied as a counterstain.
Interpretation of Immunohistochemical Staining
The immunohistochemical staining for FoxO3a and Ki-67 in whole tissue sections was preliminarily performed to confirm the reliability of the immunostaining in TMA sections. The staining patterns in the whole tissue sections were homogeneous. All stained samples were assessed in a blinded fashion by two experienced pathologists (H.A. and K.J.). The percentage of positively stained tumor cells and the intensity of staining were assessed using a semiquantitative scoring system. The intensity score was assigned as follows: 0 (negative), 1 (weak staining), 2 (intermediate staining), and 3 (strong staining). The percentage score was assigned as follows: 0 (0%-10%), 1 (11%-25%), 2 (26%-50%), 3 (51%-75%), and 4 (76%-100%). Immunoreactivity was defined as the number of cells that had positive nuclear staining patterns with minimal background staining. FoxO3a expression was scored by multiplying the intensity and proportion scores. For survival analysis, tumors with a final score of 1 or more were considered positive for FoxO3a. Tumors with a final score equal to "0" were considered negative for FoxO3a. The labeling index of Ki-67 was defined as the percentage of tumor cells with positive Ki-67 nuclear staining.
Protein Extraction and Western Blot Analysis
Four of the paired, fresh-frozen HCC and adjacent nonneoplastic liver tissues were analyzed. All fresh-frozen tissue specimens were lysed in RIPA lysis buffer, and the lysates were clarified by centrifugation (14,000 rpm) for 30 minutes at 4°C. The protein concentration was determined by using the BCA Protein Assay Kit (Pierce, Rockford, IL). Equivalent amounts of protein (40 µg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were incubated in Tris-buffered saline containing 5% nonfat milk for 1 hour to block any nonspecific protein binding. The primary anti-FoxO3a antibody was applied to the membrane at a 1:1,000 dilution and incubated overnight at 4°C. The secondary horseradish peroxidase-conjugated anti-rabbit antibody (ab6721; Abcam, Cambridge, MA) was applied to the membrane at a 1:5,000 dilution and incubated for 1 hour at room temperature. The signals were detected using the ECL detection system (Pierce). To ensure equal protein loading, anti-β-actin (sc-47778; Santa Cruz Biotechnology, Santa Cruz, CA) was used as a control.
Cell Culture
Human HCC cell line HepG2 was purchased from the Korean Cell Line Bank (Seoul, Korea) and maintained in a humidified incubator at 37°C under an atmosphere of 5% CO 2 . Cells were cultured in RPMI (Welgene, Daegu, Korea) that was supplemented with 10% fetal bovine serum (Welgene). siRNAs  for  the  negative  control  and  FoxO3a  knockdown  (target  sequence:  sense,  5′-GUGACAUGGAGUCCAUUAUTT-3′; antisense, 5′-AUAAUGGACUCCAUGUCACTT-3′) were constructed by Cosmogenetech (Seoul, Korea). Cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The efficiency of siRNA-mediated FoxO3a protein suppression was assessed via Western blot analysis.
siRNA Transfection
Cell Proliferation Assay
The tumor cell growth rate was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich, Deisenhofen, Germany). Cells were seeded in 96-well culture plates at a density of 5 × 10 3 cells per well and grown at 37°C in a 5% CO 2 incubator for various periods (0, 1, 3, and 5 days). Then, 20 μL of 5 mg/mL MTT was added to each well and cells were incubated for 4 hours. After 4 hours, 150 μL DMSO was added to each well. After the formazan crystals were completely dissolved, sample absorbance at 570 nm was measured using a microplate reader (Bio-Rad, Hercules, CA).
Wound-Healing Assay
Cells were seeded on 12-well plates and grown to confluence. A wound was made on a uniform layer of cells using a sterile 200-µL micropipette tip. Images of the same area of the wound were taken at identical time points under magnification for 3 days. The wound size was measured using TScratch software (CSElab, Zurich, Switzerland).
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Statistical Analysis
The SPSS 21.0 software package (SPSS, Chicago, IL) was used for all statistical analyses, and χ
2 tests were used to analyze the association between FoxO3a expression and various clinicopathologic parameters. The survival curves were made by the Kaplan-Meier method, and the differences were compared using the log-rank test. Significant predictors of survival were determined by univariate survival analysis using the Cox proportional hazards model. These predictors were then used in a multivariate survival analysis to explore each variable's independent effect on survival. Two-tailed Student t tests were used to analyze differences between the control and knockdown groups for all in vitro experiments. For all tests, statistical significance was considered to be at P < .05.
Results
FoxO3a Is Overexpressed in a Subset of HCC Samples
FoxO3a expression was determined by IHC. As shown in ❚Image 1❚ and ❚Table 1❚, expression of FoxO3a was not detected in any of the 21 normal liver tissues. Only five of 187 adjacent nonneoplastic liver tissues were positive for FoxO3a immunostaining. However, we found that FoxO3a was expressed in more than half (121 cases, 64.71%) of HCC samples. FoxO3a protein levels were also analyzed in four paired HCC and adjacent nonneoplastic liver tissue samples via Western blot. Two HCC tissue samples showed increased protein levels of FoxO3A compared with their corresponding nonneoplastic liver tissues ❚Image 2❚.
Expression of FoxO3a Correlates With Various Clinicopathologic Parameters in HCC
We analyzed the correlation between FoxO3a expression and a range of clinicopathologic characteristics,
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Ahn et al / Prognostic significance of foxo3a in Hcc including multifocality, histologic grade, primary tumor size, small or large vessel invasion, and AJCC stage. FoxO3a expression was associated with the aggressive phenotypes of HCC, including high histologic grade (P < .001), advanced T stage (P = .009), advanced AJCC stage (P = .031), and small vessel invasion (P < .001) ❚Table 2❚.
FoxO3a Overexpression Correlates With Poor DiseaseFree Survival in Patients With HCC
The association between conventional prognostic factors and patient survival was explored. Univariate survival analyses revealed histologic grade (P = .006), T stage (P < .001), AJCC stage (P < .001), small and large vessel invasion (P < .001), and perineural invasion (P = .009) as predictors of poor disease-free survival (DFS) in patients with HCC ❚Table 3❚. Similarly, histologic grade (P = .006), primary tumor size (P = .024), T stage (P = .003), AJCC stage (P = .005), small vessel invasion (P < .001), and large vessel invasion (P = .013) were negatively correlated with overall survival (Table 3 ). The prognostic value of FoxO3a for survival in patients with HCC was determined by comparing patients with positive and negative FoxO3a expression. FoxO3a expression was demonstrated as a predictor of poor DFS by univariate Cox regression analysis (P = .013). In addition, multivariate Cox regression analysis revealed the independent prognostic significance of FoxO3a expression (P = .018) ❚Table 4❚. The Kaplan-Meier survival curves revealed that expression of FoxO3a was a significant indicator Since Ki-67 labeling index has been known as a prognostic factor for HCC, 21 we evaluated the Ki-67 index as a prognostic factor, as well as the additive effect of FoxO3a expression, for discriminating patients with poor prognosis. The DFS for patients with a high Ki-67 index, which was defined as 10% or more, was shorter (50.5 months) compared with patients with a low Ki-67 index (79.7 months). The difference was not statistically significant when we performed the log-rank test (P = .143). However, the Breslow (generalized Wilcoxon) test showed a significant difference (P = .018). The Breslow test is more likely to detect early differences in the two survival distributions, whereas the log-rank test is more sensitive to differences at later outcomes. The KaplanMeier survival curves revealed that patients with a high Ki-67 index had a poor survival until the first 3 years of follow-up, but no significant difference was found after 3 years ( Figure 1C) Pos tumors were associated with poor DFS (log-rank test, P = .023) ( Figure 1D ). The remaining three groups showed no differences. For overall survival, both Ki-67 and FoxO3a did not show any prognostic significance.
FoxO3a Expression Levels Are Associated With Cell Proliferation in HCC
To estimate the role of FoxO3a in HepG2 cells, we artificially knocked down the expression of FoxO3a using a FoxO3a-specific siRNA. Knockdown of FoxO3a was confirmed by Western blot ❚Figure 2A❚. After knockdown of FoxO3a, cell proliferation was measured for 1 ❚Image 1❚ (cont) The normal (A) and adjacent nonneoplastic (B) tissues were negative for FoxO3a, and a subset of HCCs shows negative (C), weak (D), intermediate (E), and strong (F) staining (×400). 
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AJCP / Original article to 5 days using the MTT assay. We found that decreasing FoxO3a expression in HepG2 cells inhibited cell proliferation compared with control cells. As shown in Figure  2B , siRNA knockdown of FoxO3a significantly reduced the cell growth rate (t test, P = .004). Since Ki-67 immunostaining has been used as a marker for cell proliferation, we examined the relationship between FoxO3a expression and the Ki-67 index of clinical HCC samples. Tumors with positive FoxO3a expression were significantly associated with a higher Ki-67 index (t test, P < .001) ( Figure 2C ).
Suppression of HepG2 Cell Migration Induced by Knockdown of FoxO3a Expression
Cell migration was investigated using a wound-healing assay. Three days after wounding, HepG2 cells transfected with FoxO3a siRNA migrated to cover 60% of the initial wound area, whereas the control cells covered more than 90% of the wound area ❚Figure 3❚ and ❚Image 3❚. Knockdown 
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❚Figure 1❚ Kaplan-Meier survival curves of patients with hepatocellular carcinoma are stratified based on the expression levels of FoxO3a and Ki-67 index. A, Disease-free survival according to FoxO3a expression (log-rank test, P = .011). B, Overall survival according to FoxO3a expression (log-rank test, P = .155). C, Disease-free survival according to Ki-67 index (Breslow test, P = .018). D, Disease-free survival according to combined Ki-67 and FoxO3a expression (log-rank test, P = .023).
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Discussion
Previous studies reported that FoxO3a functions as a tumor suppressor. Relative to normal tissues, the nuclear expression of FoxO3a is decreased in some human cancers, including prostate, 22 breast, 9 and gastric adenocarcinoma. 12 In contrast, other studies have demonstrated that FoxO3a expression is higher in certain cancers, such as gastric and nasopharyngeal cancer, than in adjacent normal tissue. 10, 14 Only one study has evaluated the level of FoxO3a protein expression in paired HCC and adjacent normal liver tissues. Using IHC, Lu et al 8 showed that FoxO3a was more highly expressed in adjacent normal liver tissue compared with HCC tissues. However, our results revealed opposite findings, with nuclear FoxO3a in HCC tissues being increased compared with adjacent nonneoplastic and normal liver tissues. We had performed Western blot analysis with the same anti-FoxO3a antibody in fresh-frozen liver tissues, and all nonneoplastic liver tissues showed no FoxO3a expression. As the Western blot is more sensitive and specific for detecting protein expression, our findings may be considered more convincing. This result seems paradoxical given the known tumor-suppressive role of FoxO3a in human cancers. However, the oncogenic effect of FoxO3a has recently been identified in some cancer types and is thought to be due to varied interactions between FoxO3a and other major transcription factors. [15] [16] [17] [18] [19] 23, 24 Similar to these findings, our results support a possible oncogenic role for FoxO3a in HCC. and pulmonary adenocarcinoma. 13 In these studies, a decrease in FoxO3a expression was significantly associated with advanced phenotypic features of the tumor and poor patient survival, suggesting the tumor-suppressive role of FoxO3a. In lung adenocarcinoma, low FoxO3a expression correlated with high histologic grade, advanced TNM stage, frequent lymph node metastasis, and poor patient survival. 13 In gastric cancer, low FoxO3a expression was significantly correlated with larger tumor size, poor histologic grade, deeper invasion, local lymph node metastasis, distant metastasis, higher AJCC stage, and poor survival. 12, 14 In nasopharyngeal carcinoma, low expression of FoxO3a was significantly correlated with T stage, lymph node metastasis, distant metastasis, and poor clinical outcome. 10 In breast cancer, positive FoxO3a expression showed a significant association with estrogen receptor positivity, low histologic grade, low TNM stage, and favorable prognosis. 9, 11 In ovarian cancer, tumors that were negative for FoxO3a expression were significantly associated with short overall patient survival. 7 Nuclear accumulation of FoxO3a had a significant positive correlation with the response to neoadjuvant therapy and was linked to better overall survival in esophageal squamous cell carcinoma. 6 However, the oncogenic role of FoxO3a was also demonstrated in breast cancer, 15, 19 HCC, 16 anaplastic thyroid cancer, 17 and colon cancer. 24 In the study of 120 breast cancer samples, tumors with strong nuclear expression of FoxO3a revealed a poor clinical outcome. 15 The tumor size was decreased by knockdown of FoxO3a in MDA-MB-231 cells in an orthotopic mouse xenograft model for breast cancer, and FoxoO3a promoted invasion and migration via upregulating matrix metalloproteinases. 19 Upregulation of FoxO3a in HCC cell lines (HepG2 and Hep3B) revealed increased cell proliferation in serum-deprived culture. 16 Nuclear FoxO3a promoted cell cycle progression by cyclin A1 upregulation, promoting proliferation of human anaplastic thyroid carcinoma cell lines. 17 In a study of 113 colon cancer samples, tumors with both nuclear FoxO3a and β-catenin expression showed poor survival. 24 Expression of FoxO3a in HCC tissues has been previously investigated via immunohistochemical staining. Lu et al 8 evaluated 91 HCC tissues and revealed that high expression of FoxO3a correlated significantly with low histological grade and favorable prognosis. We analyzed the prognostic impact of FoxO3a expression in 187 patients with HCC with long-term follow-ups. We also analyzed the association of FoxO3a expression with multiple clinicopathologic features and patient survival. In contrast to the previous study, overexpression of FoxO3a was significantly correlated with adverse clinicopathologic features such as high histologic grade, advanced AJCC stage, blood vessel invasion, and poor DFS. The possible explanation for this discrepancy is the difference in the study population. In the study by Lu et al, 8 although FoxO3a expression was associated with the presence of cirrhosis, more than half of the patients did not have cirrhosis, which could have influenced the results of the survival analysis due to heterogeneity of the study population. On the other hand, most patients included in our study were diagnosed with underlying cirrhosis due to mainly chronic viral hepatitis or alcoholic hepatitis. Furthermore, FoxO3a expression was not associated with Child Pugh class in our patients (χ 2 test, P = .312), which indicates our results to be unbiased by heterogeneity of the study sample. Consequently, our data revealed that FoxO3a expression is associated with aggressive features in HCC and behaves like an oncogenic transcription factor. Our results indicate that overexpression of FoxO3a is a biomarker for HCC and predicts poor prognosis. Similar to these results, FoxO3a expression has been reported to have prognostic value in invasive ductal carcinoma (IDC) in breast tissues. 15 The nuclear localization of FoxO3a is ❚Image 3❚ Inhibition of FoxO3a expression in a HepG2 cell line suppressed cell migration in an in vitro wound-healing assay. The representative images of a wounded monolayer of HepG2 cell 0 and 3 days after plating.
significantly associated with frequent lymph node metastasis and poor survival in patients with IDC. 15 We showed that FoxO3a is expressed in HepG2 cells. We then employed siRNA to knock down FoxO3a expression in a HepG2 cell line. Our results showed that downregulation of FoxO3a inhibited cellular proliferation and migration. In agreement with our results, Liang et al 16 have demonstrated that FoxO3a behaves as a growth factor in serum-deprived HCC cells and mediates serotonin-induced proliferation. Recently, additional research has suggested that FoxO3a plays a role in tumorigenesis, tumor expansion, and metastasis through a different mechanism in many cancer types. Storz et al 19 suggested that decreased levels of serum factors, such as insulin-like growth factor 1, permit nuclear reentry of FoxO3a during tumor progression. In the nucleus, FoxO3a induces the expression of matrix metalloproteinase (MMP)-9 and MMP-13, which increases the invasive potential of tumor cells by promoting extracellular matrix degradation. Bakker et al 26 showed that FoxO3a plays an important role in the survival of tumor cells by inhibiting hypoxia-inducible factor 1 (HIF1)-induced apoptosis in response to hypoxic stress. FoxO3a induces transcription of CITED2, a protein that negatively regulates HIF1 activity and inhibits HIF1-induced apoptosis by repressing the expression of the proapoptotic HIF1 targets Nix and Rtp80. Furthermore, Tenbaum et al 24 demonstrated that β-catenin inhibits FoxO3a-induced apoptosis and that the interaction between FoxO3a and β-catenin induces metastasis in colon cancer. They have suggested that FoxO3a and β-catenin regulate common target genes that are involved in increasing cell motility and migration, angiogenesis, and metastasis.
In conclusion, we have shown that overexpression of FoxO3a is associated with aggressive phenotypes and poor prognosis in patients with HCC, and downregulation of FoxO3a expression in an HCC cell line inhibits cell proliferation and migration. Our results may be considered to contribute to the understanding of the oncogenic functions of FoxO3a in HCC. Further investigations are required to clarify the controversial functions of FoxO3a and to determine the complex mechanisms giving rise to its diverse roles in HCC.
